-
Mashup Score: 3German Lymphoma Alliance - 1 year(s) ago
The clinical course of mantle cell lymphoma (MCL) is highly variable. Lower age, better performance status, lower serum lactate-dehydrogenase (LDH) activity, and lower white blood cell (WBC) count at first diagnosis have been shown to be associated with longer progression-free and overall survival in patients with MCL suitable for moderately intensive chemotherapy. Furthermore, the tumour cell proliferation rate Ki-67 index has been identified as strong prognostic marker additional to clinical patient
Source: www.german-lymphoma-alliance.deCategories: Hem/Oncs, Latest HeadlinesTweet
-
Mashup Score: 1German Lymphoma Alliance - 1 year(s) ago
The clinical course of mantle cell lymphoma (MCL) is highly variable. Lower age, better performance status, lower serum lactate-dehydrogenase (LDH) activity, and lower white blood cell (WBC) count at first diagnosis have been shown to be associated with longer progression-free and overall survival in patients with MCL suitable for moderately intensive chemotherapy. Furthermore, the tumour cell proliferation rate Ki-67 index has been identified as strong prognostic marker additional to clinical patient
Source: www.german-lymphoma-alliance.deCategories: Hematologists1, Latest HeadlinesTweet-
RT @HematoRules: @MSubklewe #ITC23 ➡️ CAR-HEMATOTOX … great tool ✅ https://t.co/bTlC7CITQY ➡️ Antibiotics and #ICATH … interesting relati…
-
-
Mashup Score: 0iwCAR-T Session III: CAR-T therapy in AML: ongoing challenges and strategies to improve patient outcomes - 2 year(s) ago
The 5th International Workshop on CAR-T (iwCAR-T) took place in Scottsdale, AZ, on 14 – 16 April, 2023, and brought…
Source: VJHemOncCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
We're pleased to bring you another weekly podcast! Tune in as experts David Sallman (@MoffittNews), @MSubklewe & @Roma_Shap discuss challenges with implementing CAR-T therapy in AML, strategies to improve patient outcomes & more, at #iwCART23: 🎧 https://t.co/MYiFvWNJY5 #LeuSM https://t.co/A6hmaXCUvB
-
-
Mashup Score: 0
Marion Subklewe, MD, Ludwig-Maximilians University, Munich, Germany, shares some insights into the current status of T-cell bispecific antibodies in the…
Source: VJHemOncCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
#ISAL2023 | @MSubklewe of @LMU_Muenchen shares some insights into the current status of bispecifics in AML and challenges to overcome. Watch here: 👉https://t.co/ZLt7avBQrT👈 #AMLsm #LeuSM #ImmunoOnc #HemOnc
-
-
Mashup Score: 2Exploring strategies to mitigate T-cell exhaustion: treatment-free intervals & small molecules - 2 year(s) ago
In this video, Marion Subklewe, MD, Ludwig-Maximilians University of Munich, Munich, Germany, shares some insights into how chronic treatment with…
Source: VJHemOncCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
Learn more about strategies being explored to mitigate T-cell exhaustion in our interview with @MSubklewe of @LMU_Muenchen: 👉https://t.co/AR6sg2V0lC👈 @TheEBMT @EHA_Hematology #CART23 #HemOnc #CARTcell #ImmunoOnc
-
-
Mashup Score: 2Exploring strategies to mitigate T-cell exhaustion: treatment-free intervals & small molecules - 2 year(s) ago
In this video, Marion Subklewe, MD, Ludwig-Maximilians University of Munich, Munich, Germany, shares some insights into how chronic treatment with…
Source: VJHemOncCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
T-cell exhaustion is a major challenge & impacts patient response to novel immunotherapies. Find out more about strategies to mitigate T-cell exhaustion in our interview with @MSubklewe (@LMU_Muenchen): 🎥 https://t.co/ZEnm35Q7Vw @TheEBMT @EHA_Hematology #CART23 #ImmunoOnc
-
-
Mashup Score: 1Looking forward to ISAL 2023 - 2 year(s) ago
Marion Subklewe, MD, Ludwig-Maximilians University of Munich, Munich, Germany, shares some insights into the upcoming 18th International Symposium on Acute…
Source: VJHemOncCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
Next month, we'll be heading to #ISAL2023 to speak with experts who will bring you the latest in acute leukemias! Find out more below: 👉https://t.co/5XI4ptGqJ9👈 #ISALXVIII #AMLsm #ALLsm #LeuSM #HemOnc @MSubklewe @acuteleukemias
-
-
Mashup Score: 1Advantages of bispecific antibodies over CAR-T therapy in LBCL - 2 year(s) ago
Marion Subklewe, MD, Ludwig-Maximilians-University of Munich, Munich, Germany, comments on the development of novel bispecific antibodies (bsAbs) for large B-cell…
Source: VJHemOncCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
Marion Subklewe (@MSubklewe) of @LMU_Muenchen discusses the efficacy of bispecific antibodies versus CAR-T therapy in LBCL: 🎥: https://t.co/MQjWgKHB1a @COSTEMCongress #COSTEM22 #HemOnc #LymSM #ImmunoOnc
-
-
Mashup Score: 2Prof. Marion Subklewe- T-cell exhaustion induced by continuous bispecific molecule exposure - 2 year(s) ago
Listen to Prof. Marion Subklewe- T-cell exhaustion induced by continuous bispecific molecule exposure by CME Congresses #np on #SoundCloud
Source: SoundCloudCategories: Hem/Oncs, Latest HeadlinesTweet-
Dr @MSubklewe for @TheIACH News. Thank you for such an in depth analysis of T cell exhaustion when using bispecific antibodies. Superb arricle in @BloodJournal @ASH_hematology @MyelomaTeacher @IMFjimMYELOMA https://t.co/HFLvCLfdtL
-
-
Mashup Score: 1Prof. Marion Subklewe- T-cell exhaustion induced by continuous bispecific molecule exposure - 2 year(s) ago
Listen to Prof. Marion Subklewe- T-cell exhaustion induced by continuous bispecific molecule exposure by CME Congresses #np on #SoundCloud
Source: SoundCloudCategories: Hem/Oncs, Latest HeadlinesTweet-
Dr @MSubklewe for @TheIACH News- T-cell exhaustion induced by continuous bispecific molecule exposure https://t.co/iBO9mrUKCu
-
RT @HematoRules: @MSubklewe #ITC23 ➡️ CAR-HEMATOTOX … great tool ✅ https://t.co/bTlC7CITQY ➡️ Antibiotics and #ICATH … interesting relati…